标题
Harnessing NK Cells for Cancer Treatment
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-12-06
DOI
10.3389/fimmu.2019.02836
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy
- (2019) Elisa Zaghi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
- (2019) Simona Sivori et al. Cellular & Molecular Immunology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- NK cells to cure cancer
- (2019) Clara Di Vito et al. SEMINARS IN IMMUNOLOGY
- Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221
- (2019) Anna V Tinker et al. CLINICAL CANCER RESEARCH
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
- (2019) Kyle B. Lupo et al. Cancers
- Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
- (2019) Ziqing Chen et al. Cancers
- The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
- (2019) Haoyu Sun et al. Frontiers in Immunology
- NK Cell-Based Immunotherapy for Hematological Malignancies
- (2019) Simona Sivori et al. Journal of Clinical Medicine
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies
- (2018) Sandro Matosevic Journal of Immunology Research
- Not All Immune Checkpoints Are Created Equal
- (2018) Annika De Sousa Linhares et al. Frontiers in Immunology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression
- (2018) Silvia Pesce et al. Frontiers in Immunology
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
- (2017) Laura Chiossone et al. SEMINARS IN IMMUNOLOGY
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
- (2017) Veronika Kremer et al. Journal for ImmunoTherapy of Cancer
- Exploitation of natural killer cells for the treatment of acute leukemia
- (2016) Rupert Handgretinger et al. BLOOD
- Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
- (2016) A. Curti et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction
- (2015) Claudia A Nold-Petry et al. NATURE IMMUNOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
- (2015) HIDEO KOMITA et al. ONCOLOGY REPORTS
- B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
- (2015) Silvia Pesce et al. OncoImmunology
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
- (2014) Alessandro Isidori et al. Expert Review of Hematology
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- TLR/NCR/KIR: Which One to Use and When?
- (2014) Simona Sivori et al. Frontiers in Immunology
- Reversal of natural killer cell exhaustion by TIM-3 blockade
- (2014) Anne Gallois et al. OncoImmunology
- KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts
- (2013) E. Marcenaro et al. BLOOD
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
- (2013) Haoyu Sun et al. CYTOKINE
- Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells
- (2013) Franco Locatelli et al. Frontiers in Immunology
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation
- (2011) Emanuela Marcenaro et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Melanoma drug wins US approval
- (2011) Heidi Ledford NATURE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
- (2010) N. K. Bjorkstrom et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
- (2010) L. Moretta et al. BLOOD
- T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B
- (2010) Ying Ju et al. JOURNAL OF HEPATOLOGY
- Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction
- (2009) E. Marcenaro et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
- (2008) D. Pende et al. BLOOD
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now